Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,701 to 4,720 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| A+AVD vs ABVD: serious adverse events | 284 of 662 178 of 659 | 15.9 points 10.8 to 20.9 | 1,321 | NCT01712490 A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma |
| Proactive Outreach vs Usual Care: Number of Participants Self-Reporting 7-Day Abstinence From Cigarettes | 119 of 620 96 of 701 | 5.5 points 1.5 to 9.5 | 1,321 | NCT01737281 Proactive Outreach for Smokers in VA Mental Health |
| Q/LAIV (MEDI3250) vs All FluMist: The Number of Serosusceptible Participants Within Each Treatment Arm Who Experience A/H1N1 Strain-specific Seroresponse Post Dose. | 59 of 889 30 of 429 | -0.4 points -3.5 to 2.4 | 1,318 | NCT00860067 A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age |
| Q/LAIV (MEDI3250) vs All FluMist: The Number of Serosusceptible Participants Within Each Treatment Arm Who Achieved a A/H1N1 Strain-specific HAI Antibody Titer ≥ 32 Post Dose. | 17 of 889 5 of 429 | 0.7 points -0.9 to 2.1 | 1,318 | NCT00860067 A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age |
| Phase I vs Phase II: deaths from any cause | 2 of 847 1 of 470 | 0.0 points -1.0 to 0.7 | 1,317 | NCT01643707 Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady) |
| CPAP vs Surfactant: Survival Without Bronchopulmonary Dysplasia (BPD) | 346 of 663 320 of 653 | 3.2 points -2.2 to 8.6 | 1,316 | NCT00233324 Surfactant Positive Airway Pressure and Pulse Oximetry Trial |
| Rilonacept 160 mg vs Placebo: serious adverse events | 31 of 985 13 of 330 | -0.8 points -3.6 to 1.3 | 1,315 | NCT00856206 Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE) |
| CT-P59 40 mg/kg Group (Part 2) vs Placebo Group (Part 2): Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection up to Day 28 in All Randomized Patients (Part 2) | 16 of 656 53 of 659 | -5.6 points -8.1 to -3.2 | 1,315 | NCT04602000 A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection |
| Clostridium Difficile Vaccine (Pooled Lots) vs Placebo: deaths from any cause | 2 of 983 2 of 331 | -0.4 points -2.0 to 0.3 | 1,314 | NCT03579459 Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age |
| Clostridium Difficile Vaccine (Pooled Lots) vs Placebo: serious adverse events | 41 of 983 15 of 331 | -0.4 points -3.4 to 1.9 | 1,314 | NCT03579459 Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age |
| Arm I (Chemo +/- Bevacizumab) vs Arm II (Chemo, Cetuximab, +/- Bevacizumab): deaths from any cause | 593 of 657 570 of 656 | 3.4 points -0.1 to 6.8 | 1,313 | NCT00946712 S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer |
| Arm I (Doxorubicin, Cisplatin, Paclitaxel) vs Arm II (Paclitaxel, Carboplatin): deaths from any cause | 271 of 647 280 of 665 | -0.2 points -5.5 to 5.1 | 1,312 | NCT00063999 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer |
| Arm I (Doxorubicin, Cisplatin, Paclitaxel) vs Arm II (Paclitaxel, Carboplatin): serious adverse events | 217 of 647 156 of 665 | 10.1 points 5.2 to 14.9 | 1,312 | NCT00063999 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer |
| PR5I vs INFANRIX™ Hexa: serious adverse events | 6 of 653 10 of 659 | -0.6 points -1.9 to 0.7 | 1,312 | NCT01480258 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) |
| Treatment vs Placebo: deaths from any cause | 1 of 658 1 of 654 | -0.0 points -0.7 to 0.7 | 1,312 | NCT04308668 Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2 |
| Treatment vs Placebo: serious adverse events | 6 of 658 11 of 654 | -0.8 points -2.2 to 0.5 | 1,312 | NCT04308668 Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2 |
| Arm A: (Enzalutamide) vs Arm B: (Enzalutamide, Abiraterone, Prednisone): Number of Participants Who Has Experienced at Least One Toxicity (Defined as a Grade 3 or Higher Adverse Event Deemed at Least Possibly Related to Treatment) | 167 of 657 287 of 654 | -18.5 points -23.4 to -13.4 | 1,311 | NCT01949337 Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer |
| Arm A: (Enzalutamide) vs Arm B: (Enzalutamide, Abiraterone, Prednisone): deaths from any cause | 372 of 657 339 of 654 | 4.8 points -0.6 to 10.1 | 1,311 | NCT01949337 Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer |
| Arm A: (Enzalutamide) vs Arm B: (Enzalutamide, Abiraterone, Prednisone): serious adverse events | 232 of 657 269 of 654 | -5.8 points -11.0 to -0.6 | 1,311 | NCT01949337 Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer |
| PF-07321332 300 mg + Ritonavir 100 mg vs Placebo: Number of Participants With Progression to a Worsening Status in 1 or More Self-reported COVID-19 Associated Symptoms Through Day 28-mITT Population | 507 of 666 483 of 645 | 1.2 points -3.4 to 5.9 | 1,311 | NCT04960202 EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19 |
Code
curl "https://conductscience.org/api/comparisons/v1?page=236"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=236
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01712490-sae",
"title": "A+AVD vs ABVD: serious adverse events",
"summary": "284 of 662 against 178 of 659; risk difference 15.9 points, 95% interval 10.8 to 20.9; NCT01712490, A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma",
"record": "/library/comparisons/NCT01712490-sae",
"nct_id": "NCT01712490",
"kind": "serious-adverse-events",
"participants": 1321,
"risk_difference": {
"value": 0.15889679960023656,
"lower": 0.10772020091088992,
"upper": 0.2089003984637372
},
"group_1": "284 of 662",
"group_2": "178 of 659",
"difference": "15.9 points",
"interval": "10.8 to 20.9",
"trial_title": "A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma"
},
{
"id": "NCT01737281-70004451",
"title": "Proactive Outreach vs Usual Care: Number of Participants Self-Reporting 7-Day Abstinence From Cigarettes",
"summary": "119 of 620 against 96 of 701; risk difference 5.5 points, 95% interval 1.5 to 9.5; NCT01737281, Proactive Outreach for Smokers in VA Mental Health",
"record": "/library/comparisons/NCT01737281-70004451",
"nct_id": "NCT01737281",
"kind": "outcome",
"participants": 1321,
"risk_difference": {
"value": 0.05498826561133863,
"lower": 0.015019421103793812,
"upper": 0.09537339112701917
},
"group_1": "119 of 620",
"group_2": "96 of 701",
"difference": "5.5 points",
"interval": "1.5 to 9.5",
"trial_title": "Proactive Outreach for Smokers in VA Mental Health"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=237",
"request_id": "Vfmb-COkqCOOFAJV"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant